TDScreen will be accessible to National Council for Mental Wellbeing Members at no cost

Orem, Utah – April 28, 2025 – Videra Health™, a leading AI platform for behavioral health providers, has announced the launch of TDScreen, the first-ever automated, video based, AI solution on the market to screen for Tardive Dyskinesia (TD) risk, a chronic, involuntary movement disorder that can develop as a side effect of long-term use of certain medications, particularly antipsychotic drugs. National Council for Mental Wellbeing Members, a membership organization that drives policy and social change on behalf of more than 3,400 mental health and substance use treatment organizations and the more than 10 million children, adults and families they serve, will now have access to TDScreen at no cost.

TD presents unique screening challenges even for experienced clinicians and remains underdiagnosed despite affecting millions of Americans taking antipsychotic medications. With its involuntary movements often mistaken for nervousness, aging, or other conditions, the gap in recognition represents not just a clinical challenge, but a deeply human one that affects quality of life and treatment outcomes.

“Videra Health is thrilled to be able to launch a first-of-its-kind innovative solution to screen for TD risk, effectively,” said Loren Larsen, CEO of Videra Health. “TDScreen and our broader AI platform aren’t about replacing clinician judgment—they’re about enhancing it. By automating routine screenings, we free healthcare providers to focus on what matters most: the human connections and complex decision-making that drive quality care. Larsen added, “We are delighted to offer TDScreen to the National Council for Wellbeing Members, an important organization leading policy in mental health. ” 

“We’re proud to partner with Videra Health to provide TDScreen at no cost to our 3,200+ member organizations,” said Charles Ingoglia, president and CEO of the National Council for Mental Wellbeing. “This AI tool helps close the gap in detecting Tardive Dyskinesia, enabling earlier intervention and better outcomes. It’s a strong step forward in using technology to enhance mental health care.”

TDScreen uses advanced video analysis technology to evaluate patients for potential TD symptoms quickly and efficiently. With TDScreen, patients on antipsychotics can easily complete virtual screenings to accurately assess their risk factors in their own environments and enable providers to monitor or modify their treatment plans. The TDScreen tool is based on the Abnormal Involuntary Movement Scale (AIMS), a comprehensive clinician-rated scale designed to specifically evaluate involuntary movements. Employing advanced AI video technology, TDScreen efficiently assesses and quantifies the risk of TD in less than 5 minutes. The resulting score generated by this assessment can aid in clinical decision-making and management strategies.

Additional benefits of TD Screen include:

• Providers can effortlessly enroll their patients who are receiving antipsychotics for automated TDScreen assessments at predetermined intervals, ensuring proactive and consistent healthcare management.
• An intuitive interface simplifies scheduling tailored screening and monitoring protocols, accompanied by automated reminders and notifications to keep both providers and patients engaged every step of the way.

To learn more about TDScreen visit www.tdscreen.ai.

About Videra Health™

Videra Health is a leading AI-driven patient engagement and health assessment platform that empowers providers and healthcare organizations to proactively identify, triage, and monitor patients, closing care gaps using linguistic, audio and video analysis at scale. The FDA-registered digital platform transforms how doctors and healthcare systems interact and track a patient’s journey, illuminating the hidden depths of patient behavior and outcomes. Videra Health connects providers and patients anytime, anywhere, between visits and post-discharge via written and video assessments that translate into actionable quantitative and qualitative patient data. The platform streamlines diagnoses, enhances care accessibility, optimizes workflows and drives down costs for providers and healthcare systems.

For more information, visit www.viderahealth.com.

About National Council for Mental Wellbeing

The National Council for Mental Wellbeing is a membership organization that drives policy and social change on behalf of more than 3,200 mental health and substance use treatment organizations and the more than 10 million children, adults and families they serve. We advocate for policies to ensure access to high-quality services. We build the capacity of mental health and substance use treatment organizations. And we promote greater understanding of mental wellbeing as a core component of comprehensive health and health care. Through our Mental Health First Aid (MHFA) program, we have trained more than 3 million people in the U.S. to identify, understand and respond to signs and symptoms of mental health and substance use challenges.

For more information, please visit https://www.thenationalcouncil.org. 

###

Media Contact:
Videra Health
Stacy Callahan
stacy@astonishmediagroup.com